Business Segments · Research and development expense
Neuroscience — Research and development expense
Medtronic Neuroscience — Research and development expense decreased by 8.4% to $153.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.7%, from $152.00M to $153.00M.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026
How to read this metric
Higher spending suggests a commitment to future growth through innovation, while lower spending might indicate a focus on short-term margin expansion or a maturing product cycle.
Detailed definition
This includes all costs associated with the discovery, development, and clinical testing of new neuroscience technologie...
Peer comparison
Comparable to R&D intensity metrics across the medical device and pharmaceutical industries.
Metric ID:
mdt_segment_neuroscience_research_and_development_expenseHistorical Data
11 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $143.25M | $143.25M | $143.25M | $143.25M | $153.00M | $158.00M | $152.00M | $172.00M | $157.00M | $167.00M | $153.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +6.8% | +3.3% | -3.8% | +13.2% | -8.7% | +6.4% | -8.4% |
| YoY Change | — | — | — | — | +6.8% | +10.3% | — | — | +2.6% | +5.7% | +0.7% |
Range$143.25M – $172.00M
CAGR+2.7%
Avg YoY Growth+5.2%
Median YoY Growth+5.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Medtronic's neuroscience — research and development expense?
- Medtronic (MDT) reported neuroscience — research and development expense of $153.00M in Q1 2026.
- How has Medtronic's neuroscience — research and development expense changed year-over-year?
- Medtronic's neuroscience — research and development expense increased by 0.7% year-over-year, from $152.00M to $153.00M.
- What does neuroscience — research and development expense mean?
- Spending on developing new neuroscience products and clinical research.